

Supplementary Table 3. Clinical and Immunological Characteristics of Patients at High Risk for Latent Pathogen Reactivation

Patient ID	Sex (0=M,1=F)	Age at onset (mo)	Age at first RTX(mo)	Disease duration before RTX (mo)	Clinical diagnosis	Renal biopsy	IVIg use, 1 yr pre-RTX	Baseline CD19 (cells/ μ L)	Baseline IgG(g/L)	Baseline IgE (IU/mL)	6mo CD19 (cells/ μ L)	6mo IgG(g/L)	6mo IgE (IU/mL)	Concomitant immunosuppressants	Pathogen type	Time of infection detection	Liver dysfunction	Renal dysfunction	Relapses within 1 yr after RTX
#1	1	112.7	114.9	2.2	SSNS	MCD	YES	466.804	4.65	151	3.06	5.89	23.6	GC	EBV	6mo	NO	NO	2
#2	0	31.5	168.3	136.8	SSNS+FRN	NA	YES	717.53	1.08	28.3	74.46	5.27	11.5	GC+MMF	TB	6mo	NO	NO	0
#3	0	24.2	60.4	36.2	SSNS	NA	YES	269.724	7.87	6.2	240.36	8.76	5.4	GC	TB	12mo	NO	NO	0
#4	0	12	73	61	SRNS	NA	YES	157.81	7.46	36.1	17.46	8.83	7.8	GC+TAC	EBV	6mo	NO	NO	0
#5	0	21.9	109.4	87.5	SRNS+FRN	MCD	YES	181.008	4.7	1460	304.848	10.7	510	GC+TAC	TB	12mo	NO	NO	0
#6	0	39	67.7	28.7	SRNS+FRN	MCD	YES	182.665	3.18	5348	296.16	2.32	2280	GC+TAC	TB	12mo	NO	NO	2
#7	1	42.7	84	41.3	SRNS+FRN	NA	YES	266.175	3.37	111	4.256	5.99	13.3	GC+TAC	TB	6mo	NO	NO	0
#8	1	18.6	63.9	45.3	SRNS+FRN	NA	YES	641.2	6.66	26.5	102.39	6.35	9.7	GC+TAC	TB	Baseline	NO	NO	0
#9	0	31	87	56	SSNS	NA	YES	744.576	7.22	14.3	159.98	7.26	<5	NO	TB	Baseline	NO	NO	0
#10	1	138.6	148.4	9.8	SSNS+FRN	NA	YES	426.85	7.36	10.3	3.519	8.62	9.2	GC+TAC	TB	Baseline	NO	YES	1
#11	0	25.5	44.9	19.4	SSNS+FRN	NA	NO	241.826	6.47	108	203.94	5.22	55.9	GC	EBV+TB	Baseline	NO	NO	0
#12	1	19	80	62.5	SSNS	NA	YES	345.43	4.31	64.2	341.65	7.12	16.4	NO	CMV	Baseline	NO	NO	0
#13	0	23	68	45	SSNS+FRN	NA	YES	610.5	4.85	7.8	181.643	6.8	<5	GC+MMF	EBV	Baseline	NO	NO	0
#14	0	36	102	63.7	SSNS+FRN	NA	YES	409.572	10.01	988	39.895	9.87	1070	GC+TAC	EBV	Baseline	YES	NO	0
#15	0	23	163	140	SSNS+FRN	FSGS	YES	478.21	6.48	118	226.192	8.17	30.6	GC+TAC	EBV	Baseline	YES	YES	0
#16	0	29.5	64	34.5	SSNS+FRN	NA	YES	190.665	5.45	38.2	58.09	7.01	36.4	GC+TAC	EBV	Baseline	NO	NO	0
#17	0	33	64.4	31.4	SSNS+FRN	NA	YES	190.232	8.47	1.6	3.21	8.82	2.36	GC	EBV	Baseline	NO	NO	0
#18	1	36	116.3	80.3	SSNS+FRN	MCD	YES	359.78	11.6	31.7	157.07	13.2	15.5	TAC	TB	Baseline	NO	YES	0
#19	0	18.1	125.5	107.4	SSNS+FRN	NA	YES	241.623	8.12	15.2	97.04	7.03	12.2	GC+TAC	EBV+TB	Baseline	NO	NO	0
#20	0	61.5	87.6	26.1	SSNS+FRN	NA	YES	232.704	9.73	219	270.68	11	245	GC+TAC	EBV	Baseline	NO	NO	0
#21	0	31.1	165	133.9	SSNS+FRN	MCD	YES	538.65	7.37	78	60.62	8.35	285	GC+TAC	TB	Baseline	NO	NO	0
#22	0	101.7	178.3	76.6	SSNS+FRN	MCD	YES	168.48	7.35	789	36.33	NA	NA	GC+TAC	EBV	Baseline	NO	YES	0
#23	0	75.5	82.6	7.1	SRNS+FRN	MCD	YES	559.468	3.22	110	44.64	5.59	19.5	GC+TAC	EBV+CMV	Baseline	NO	YES	0
#24	0	51.3	58.9	7.6	SRNS+FRN	FSGS	YES	1281.88	2.58	2080	7.79	4.6	77.7	GC+TAC	EBV	Baseline	NO	YES	0
#25	0	69	164.2	95.2	SSNS	MCD	YES	319.566	6.55	44	1.91	10.3	25.1	GC+TAC	EBV	Baseline	NO	YES	0

High-risk group was defined as patients with EBV or CMV reactivation/activation, or latent/active tuberculosis within 1 year before or after RTX. Data are shown for each patient individually.

Abbreviations: RTX, rituximab; EBV, Epstein-Barr virus; CMV, cytomegalovirus; TB, tuberculosis; SSNS, steroid-sensitive nephrotic syndrome; SRNS, steroid-resistant nephrotic syndrome; MCD, minimal change disease; FSGS, focal segmental glomerulosclerosis; IVIG, intravenous immunoglobulin; GC, glucocorticoid